Creating a Robust Pricing Compliance/Audit Program That Will Provide the Most Accurate Calculations and the Ability to Verify Them
March 11, 2009
Foley Partner Lena Robins is speaking at the American Conference Institute’s (ACI) 7th Annual Advanced forum on Government Regulation of Prescription Drug Pricing, March 11 – 12, 2009 in New York, New York.
Ms. Robins is speaking on March 11, 2009 at 4:15 p.m. Her session is titled “Creating a Robust Pricing Compliance/Audit Program That Will Provide the Most Accurate Calculations and the Ability to Verify Them.” Topics to be covered include:
- Developing a compliance program that conforms to HHS OIG draft Compliance Program Guidance for the pharmaceutical industry
- Reducing risk in the three areas identified by the OIG as the most problematic:
- integrity of data
- kickbacks and illegal remuneration
- samples
- integrity of data
- Defining the relationship between the government pricing function and the compliance department
- what role does or should the finance department play?
- Weighing the pros and cons of outsourcing calculations
- what can or should be outsourced?
- ensuring that outsources calculations are correct
- what is the government’s position on outsourcing calculations?
Related Insights
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).